

Title	Suppressive effect of black tea polyphenol theaflavins in a mouse model of ovalbumin-induced food allergy
Author(s)	Ishimoto, Kenji; Konishi, Yuma; Otani, Shuichi et al.
Citation	Journal of Natural Medicines. 2023, 77, p. 604-609
Version Type	AM
URL	https://hdl.handle.net/11094/90087
rights	
Note	

Osaka University Knowledge Archive : OUKA

<https://ir.library.osaka-u.ac.jp/>

Osaka University

Suppressive effect of black tea polyphenol theaflavins in a mouse model of ovalbumin-induced food allergy

1

2 **Kenji Ishimoto^{1,2,3,4†}, Yuma Konishi^{1†}, Shuichi Otani^{2,5}, Soya Maeda^{2,5}, Yukio Ago^{3,6},**

3 **Nobumasa Hino¹, Masayuki Suzuki^{2,5}, Shinsaku Nakagawa^{1,2,3,4*}**

4 ¹Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Osaka

5 University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan

6 ²Laboratory of Innovative Food Science, Graduate School of Pharmaceutical Sciences, Osaka

7 University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan

8 ³Global Center for Medical Engineering and Informatics, Osaka University, 2-2 Yamadaoka,

9 Suita, Osaka 565-0871, Japan

10 ⁴Center for Supporting Drug Discovery and Life Science Research, Graduate School of

11 Pharmaceutical Sciences, Osaka University, Suita, Osaka 565-0871, Japan

12 ⁵Mitsui Norin Co. Ltd., R&D Group, 223-1 Miyabara, Fujieda, Shizuoka 426-0133, Japan

13 ⁶Department of Cellular and Molecular Pharmacology, Graduate School of Biomedical and

14 Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan

15 † These authors contributed equally to this work

16

17 *** Corresponding Author:**

18 Shinsaku Nakagawa, Ph.D. Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical
19 Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. Tel: +81 6 6879
20 8175. Fax: +81 6 6879 8179. e-mail: nakagawa@phs.osaka-u.ac.jp

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42 **Abstract (204 words)**

43 Food allergy is recognized as a global medical problem with increasing prevalence in
44 recent years. Currently, the treatment of food allergy mainly involves avoidance of allergens and
45 allergen-specific immunotherapy. Barring the spontaneous resolution of food allergy during the
46 growth process, this disease is difficult to treat fundamentally. In recent years, the use of
47 functional food ingredients derived from natural products has been attracting attention for their
48 prophylactic use in food allergy. Theaflavins, i.e. black tea polyphenols, are potent antioxidants
49 that have inhibitory effects on a variety of diseases. However, little is known about the
50 preventive effect of theaflavins on food allergy. In this study, we designed a mouse model of
51 food allergy and examined the effect of theaflavins using the severity of diarrhea, a symptom of
52 food allergy, as an indicator. The administration of a black tea extract rich in theaflavins or
53 theaflavin 1 (subgroup of theaflavins) to mice reduced the severity of diarrhea when compared
54 with a normal diet. A reduction in malondialdehyde levels, a key marker of lipid peroxidation,
55 was also observed. Overall, these data suggest that theaflavins may potentially inhibit food
56 allergy by alleviating oxidative stress in the colon and can be a potential food material for
57 prevention of food allergy.

58 **Keywords:**

59 Black tea extract, diarrhea, food allergy, functional food ingredients, oxidative stress,
60 theaflavins.

61

62

63 **Introduction**

64 Food allergy (FA) is globally recognized as an important medical problem. Although there
65 are no clear epidemiological data, FA affects up to 10% of the overall population and has
66 increased in prevalence over the past 20–30 years [1]; the prevalence of FA is about 6% in
67 children and 3–4% in adults [2]. The symptoms of FA include itching, abdominal pain, vomiting,
68 and diarrhea [3]. Allergen avoidance and allergen-specific immunotherapy are common in
69 patients diagnosed with FA [4, 5]. However, avoidance of allergens may result in nutritional
70 deficiencies and impaired growth in children on strictly restricted diets, whereas allergen-specific
71 immunotherapy has been noted for its limited effectiveness, safety, and sustainability. Hence,
72 new and safe functional food ingredients are expected to be utilized to prevent FA or to support
73 the ongoing treatment plan [6].

74 Black tea, one of the world's most popular beverages, has been shown in epidemiological
75 and laboratory studies to have beneficial properties, including antioxidant [7], and anti-
76 inflammatory activities [8], and reduction of cardiovascular disease risk [9]. Theaflavins (TFs),
77 which are polyphenols abundant in black tea are key to their biological activity [10]. During the
78 fermentation process of black tea, catechins are enzymatically oxidized into two linked forms
79 [11]. TFs have excellent antioxidant activity, and their hydroxyl radical scavenging ability is
80 more effective than that of the leading catechin, epigallocatechin gallate. [12]. TFs have also
81 been reported to exhibit anti-inflammatory [13] and inhibitory effects on digestive enzymes
82 leading to anti-diabetic and anti-obesity properties [14, 15]. However, little is known about the
83 anti-allergic effects of TFs. The subgroups of TFs known include theaflavin 1 (TF1), theaflavin
84 3-gallate (TF2A), theaflavin 3'-gallate (TF2B), and theaflavin 3, 3'-digallate (TF3). Among
85 these, TF2A and TF3 are effective in preventing oxazolone-induced contact hypersensitivity in

86 male ICR mice by dermal and oral administration [16]. If the suppressive effect of TFs on FA
87 can be demonstrated, it may aid in decreasing the prevalence of FA. In this study, we
88 investigated the preventive effect of black tea extract rich in TFs in a mouse model of FA.

89 **Materials and Methods**

90 **Materials**

91 Theaflavin mixture (TFM), TFM-low catechins (TFM-lc) with most of the catechins
92 removed from TFM, and TF1 were provided by Mitsui Norin Co., Ltd. (Tokyo, Japan).
93 Ovalbumin (OVA, grade V) was purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA).
94 Aluminum hydroxide gel (Alum) was purchased from Fujifilm Wako Pure Chemical Corp.
95 (Osaka, Japan).

96 **Animals**

97 The study protocol was approved by the Animal Care and Use Committee of the Graduate
98 School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (protocol number: Douyaku
99 29-3). All experimental procedures were conducted in accordance with the Guide for the Care
100 and Use of Laboratory Animals [17]. Extra care was taken to minimize animal suffering and the
101 number of animals used. Female BALB/c mice were obtained from Japan SLC Inc. (Shizuoka,
102 Japan) and acclimatized under controlled environmental conditions ($22 \pm 1^\circ\text{C}$; $50\% \pm 10\%$
103 relative humidity; 12-h light-dark cycle; lights on at 08:00 AM) for some days before the start of
104 the experiment. All animals were fed with normal powdered food (MF, Oriental Yeast Co. Ltd.,
105 Tokyo, Japan) and had *ad libitum* access to water [18]. TFM, TFM-lc, and TF1 were each

106 prepared by mixing with powdered food at a concentration of 0.02–0.20% and administration
107 was started 2 weeks prior to OVA sensitization.

108 **OVA-induced FA mouse model**

109 The experimental protocol for the OVA-induced FA mouse model was slightly modified
110 from that of Kunisawa *et al.* [19]. Briefly, eight-week-old mice were sensitized by intraperitoneal
111 injection of 100 μ L solution containing 1 mg alum and 1 mg OVA on week 0. Then, from week
112 1–5, 200 μ L of 250 mg/mL OVA was orally administered three times per week. FA symptoms
113 were evaluated using allergic diarrhea as a parameter. Allergic diarrhea was determined 30–60
114 min after OVA administration by a severity score of 0–3 (0, solid state; 1, semi-solid form; 2,
115 slurry; 3, watery state) for fecal conditions.

116 **Malondialdehyde (MDA) assay**

117 Three days after the last OVA challenge, colon tissue was collected from mice 40 min after
118 oral administration of OVA. Colon samples (approximately 100 mg) were homogenized with
119 phosphate-buffered saline (1:9 w/v). After centrifugation at $10,000 \times g$ for 5 min, the collected
120 supernatant was used for the MDA assay. The MDA levels were assessed using the
121 thiobarbituric acid (TBA) reaction described by Ohkawa *et al.* [20]. Briefly, 100 μ L of colon
122 tissue sample was mixed with 100 μ L of SDS lysis solution (50 mM Tris-HCl, 1% SDS, 10 mM
123 EDTA, 1 mM PMSF, and protease inhibitor cocktail) and incubated at room temperature for 5
124 min. To this mix, 250 μ L of 5.2 mg/mL TBA solution was added and incubated at 95°C for 60
125 min. The samples were cooled to room temperature, and centrifuged at $900 \times g$ for 5 min.
126 Absorbance of the supernatant was measured at 532 nm.

127 **Statistical analysis**

128 Statistical analysis was performed with Dunnett's multiple comparisons test or Dunn's
129 multiple comparisons test using Prism 9 (GraphPad Software, Inc., La Jolla, CA). Data are
130 presented as mean \pm standard error.

131 **Results**

132 The maximum (or total) amount of TFs in Assam black tea has been assessed by HPLC
133 and reported to be 2.12% [21]. The extraction of TFs from black tea leaves is difficult owing to
134 the small amount of TFs in black tea [22]. Synthesis of TFs by enzymatic and other methods has
135 been reported previously, but with low yield [22]. As the quantity of TFs available for long-term
136 *in vivo* studies is limited, extracts of black tea are generally used in experiments. In this study,
137 we examined the effect of TFs on FA using TFM, which contains ~42% TFs in the dry matter
138 (Supplemental Table 1). Experimental protocols for induction of FA by OVA and administration
139 of TFs are illustrated in Fig. 1. The oral challenge with OVA was performed 12 times, and the
140 severity of diarrhea was assessed 30–60 min after each challenge. After the 4th challenge,
141 diarrhea scores were lower in the group fed with TFM diet than the group fed with normal diet
142 (ND) (Fig. 2A). Statistical analysis of diarrhea scores at the 12th challenge revealed a significant
143 decrease in diarrhea scores in the 0.2% TFM group compared with the normal diet (Fig. 2B).
144 Overall, these findings indicated that TFM may suppress FA.

145 Multiple studies have demonstrated that catechins have an inhibitory effect on FA [23,
146 24]. As TFM contains ~16% catechins in the dry matter, we predicted that the FA suppression
147 effect exhibited by TFM is potentially due to catechins and not TFs. Hence, the effect on FA was
148 further examined using TFM-1c with catechins reduced to ~3% in the dry matter (TFs are ~49%

149 in the dry matter). To more directly test the suppressive effect of TFs on FA, theaflavin 1 (TF1),
150 a subgroup of TFs, was also tested simultaneously. In this study, the dose of TF1 was set at
151 0.02% because ~10% in TFM and TFM-lc corresponded to TF1 (Supplemental Table 1). As in
152 Fig. 2, diarrhea scores were lower in the TFM diet group than in the ND group after the fourth
153 challenge (Fig. 3A). The TFM-lc group with low levels of catechins was found to behave
154 similarly to the TFM group. However, the TF1 group behaved the same as the ND group until
155 the 10th challenge, but a decline in diarrhea scores were observed after the 11th challenge.
156 Statistical analysis of diarrhea scores at the 12th challenge showed that a significant decrease in
157 diarrhea scores was observed in all TFM, TFM-lc, and TF1 groups relative to the ND group (Fig.
158 3B).

159 Finally, to elucidate the mechanism of the diarrheal symptom suppression effect of TFs,
160 oxidative stress levels in colon tissue were examined. Analysis of the amount of MDA, a marker
161 of lipid peroxidation, showed that it was reduced in all TFM, TFM-lc, and TF1 groups than the
162 ND group (Fig. 4). Taken together, these findings suggested that TFs may suppress FA by
163 alleviating oxidative stress in the colon.

164 **Discussion**

165 Allergic diseases are increasing in prevalence globally, causing significant health and
166 socioeconomic losses in various countries [25]. Lifestyle and dietary changes are known to
167 contribute to the increase and exacerbation of these diseases. For example, dietary changes due
168 to decreased intake of antioxidants such as vitamin E can lead to the development of allergic
169 diseases such as FA, asthma, and rhinitis. Therefore, black tea, which contains a variety of

170 antioxidants such as TFs and catechins and is routinely available, can be a beneficial ingredient
171 as a preventive measure against allergic diseases.

172 In this study, we found that TFM and TFM-lc had inhibitory effects on FA (Figs. 2, 3).
173 Since administration of TF1 also led to FA inhibition, it was concluded that TF1 is one of the
174 active ingredients responsible for the FA suppression mediated by TFM and TFM-lc (Fig. 3B).
175 On the other hand, no suppressive effect on FA was observed for TF1 prior to the 10th OVA
176 challenge compared to TFM or TFM-lc (Fig. 3A). This may be due to the involvement of TFs
177 other than TF1, ECg, caffeine, and other polyphenols. Oral administration of TF2A and TF3 in
178 mice has been shown to suppress type I allergic symptoms in a dose-dependent manner [16].
179 ECg also has an inhibitory activity against histamine release from rat basophilic leukemia cell
180 lines [26]. These findings suggest that various components in black tea, including TF1, exert
181 inhibitory effects on FA. OVA-specific antibody production was not altered by administration of
182 TFs during the OVA sensitization or challenge phase (data not shown). Further studies are
183 required to elucidate the details of the suppressive effect of TFs on OVA-induced FA and should
184 focus on mechanisms of action other than antibody production.

185 **Conclusion**

186 In this study, we demonstrated that TFM, TFM-lc, and TF1 suppressed OVA-induced FA.
187 The antioxidant properties of these ingredients were found to contribute to the alleviation of FA.
188 Hence, given the increasing global significance of FA, daily consumption of readily available
189 black tea may aid in the prevention or treatment of FA.

190

191 **Author Contributions**

192 KI designed the study as the first author, and drafted the manuscript. YK, SO, and SM
193 collected the test data. YA, NH, and MS helped in the interpretation of results. SN directed the
194 research and reviewed the manuscript.

195 **References**

- 196 1. Sicherer SH, Sampson HA (2018) Food allergy: A review and update on epidemiology,
197 pathogenesis, diagnosis, prevention, and management. *J Allergy Clin Immunol* 141:41–
198 58. <https://doi.org/10.1016/j.jaci.2017.11.003>
- 199 2. Ganesh R, Sathiyasekeran M (2013) Food allergy in children. *Indian J Pract Pediatr*
200 15:180–188. <https://doi.org/10.2500/108854181779091407>
- 201 3. Xiong Y, Xu G, Chen M, Ma H (2022) Intestinal Uptake and Tolerance to Food Antigens.
202 *Front Immunol* 13:1–10. <https://doi.org/10.3389/fimmu.2022.906122>
- 203 4. Pavić I, Kolaček S (2017) Growth of children with food allergy. *Horm Res Paediatr*
204 88:91–100. <https://doi.org/10.1159/000462973>
- 205 5. Nicolaidis RE, Parrish CP, Bird JA (2020) Food Allergy Immunotherapy with Adjuvants.
206 *Immunol Allergy Clin North Am* 40:149–173. <https://doi.org/10.1016/j.iac.2019.09.004>
- 207 6. Trogen B, Jacobs S, Nowak-Wegrzyn A (2022) Early Introduction of Allergenic Foods
208 and the Prevention of Food Allergy. *Nutrients* 14:2565.
209 <https://doi.org/10.3390/nu14132565>

- 210 7. Gossiau A, Li S, Zachariah E, Ho CT (2018) Therapeutic Connection Between Black Tea
211 Theaflavins and Their Benzotropolone Core Structure. *Curr Pharmacol Reports* 4:447–
212 452. <https://doi.org/10.1007/s40495-018-0157-y>
- 213 8. de Mejia EG, Ramirez-Mares MV, Puangpraphant S (2009) Bioactive components of tea:
214 Cancer, inflammation and behavior. *Brain Behav Immun* 23:721–731.
215 <https://doi.org/10.1016/j.bbi.2009.02.013>
- 216 9. Arab L, Khan F, Lam H (2013) Tea consumption and cardiovascular disease risk1-3. *Am*
217 *J Clin Nutr* 98:. <https://doi.org/10.3945/ajcn.113.059345>
- 218 10. He HF (2017) Research progress on theaflavins: Efficacy, formation, and preparation.
219 *Food Nutr Res* 61:. <https://doi.org/10.1080/16546628.2017.1344521>
- 220 11. Wang H, Provan GJ, Helliwell K (2000) Tea flavonoids: Their functions, utilisation and
221 analysis. *Trends Food Sci Technol* 11:152–160. <https://doi.org/10.1016/S0924->
222 [2244\(00\)00061-3](https://doi.org/10.1016/S0924-2244(00)00061-3)
- 223 12. Yang Z, Jie G, Dong F, et al (2008) Radical-scavenging abilities and antioxidant
224 properties of theaflavins and their gallate esters in H₂O₂-mediated oxidative damage
225 system in the HPF-1 cells. *Toxicol Vitr* 22:1250–1256.
226 <https://doi.org/10.1016/j.tiv.2008.04.007>
- 227 13. Kuroda Y, Hara Y (1999) Antimutagenic and anticarcinogenic activity of tea polyphenols.
228 *Mutat Res - Rev Mutat Res* 436:69–97. [https://doi.org/10.1016/S1383-5742\(98\)00019-2](https://doi.org/10.1016/S1383-5742(98)00019-2)

- 229 14. Matsui T, Tanaka T, Tamura S, et al (2007) A-Glucosidase Inhibitory Profile of Catechins
230 and Theaflavins. *J Agric Food Chem* 55:99–105. <https://doi.org/10.1021/jf0627672>
- 231 15. Glisan SL, Grove KA, Yennawar NH, Lambert JD (2017) Inhibition of pancreatic lipase
232 by black tea theaflavins: Comparative enzymology and in silico modeling studies. *Food*
233 *Chem* 216:296–300. <https://doi.org/10.1016/j.foodchem.2016.08.052>
- 234 16. Yoshino K, Yamashita Y, Yamazaki K, et al (2011) Preventive effects of black tea
235 theaflavins on mouse type 1 allergy induced by ovalbumin. *J Technol Educ* 18:9–14
- 236 17. National Research Council (2011) *Guide for the Care and Use of Laboratory Animals* (8th
237 ed). National Academies Press, Washington, D.C. <https://doi.org/10.1258/la.2012.150312>
- 238 18. Ishimoto K, Shimada Y, Ohno A, et al (2022) Physicochemical and Biochemical
239 Evaluation of Amorphous Solid Dispersion of Naringenin Prepared Using Hot-Melt
240 Extrusion. *Front Nutr* 9:1–12. <https://doi.org/10.3389/fnut.2022.850103>
- 241 19. Kunisawa J, Arita M, Hayasaka T, et al (2015) Dietary ω 3 fatty acid exerts anti-allergic
242 effect through the conversion to 17,18-epoxyeicosatetraenoic acid in the gut. *Sci Rep* 5:1–
243 8. <https://doi.org/10.1038/srep09750>
- 244 20. Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by
245 thiobarbituric acid reaction. *Anal Biochem* 95:351–358. [https://doi.org/10.1016/0003-](https://doi.org/10.1016/0003-2697(79)90738-3)
246 [2697\(79\)90738-3](https://doi.org/10.1016/0003-2697(79)90738-3)

- 247 21. Baruah AM, Mahanta PK (2003) Fermentation Characteristics of Some Assamica Clones
248 and Process Optimization of Black Tea Manufacturing. *J Agric Food Chem* 51:6578–
249 6588. <https://doi.org/10.1021/jf030019w>
- 250 22. Takemoto M, Takemoto H (2018) Synthesis of theaflavins and their functions. *Molecules*
251 23:1–18. <https://doi.org/10.3390/molecules23040918>
- 252 23. Singh A, Demont A, Actis-Goretta L, et al (2014) Identification of epicatechin as one of
253 the key bioactive constituents of polyphenol-enriched extracts that demonstrate an anti-
254 allergic effect in a murine model of food allergy. *Br J Nutr* 112:358–368.
255 <https://doi.org/10.1017/S0007114514000877>
- 256 24. Shinozaki T, Sugiyama K, Nakazato K, Takeo T (1997) Effect of Tea Extracts, Catechin
257 and Caffeine against Type-I Allergic Reaction. *Yakugaku Zasshi* 117:448–454.
258 https://doi.org/10.1248/yakushi1947.117.7_448
- 259 25. Shams MH, Jafari R, Eskandari N, et al (2021) Anti-allergic effects of vitamin E in
260 allergic diseases: An updated review. *Int Immunopharmacol* 90:107196.
261 <https://doi.org/10.1016/j.intimp.2020.107196>
- 262 26. Matsuo N, Yamada K, Shoji K, et al (1997) Effect of tea polyphenols on histamine release
263 from rat basophilic leukemia (RBL-2H3) cells: The structure-inhibitory activity
264 relationship. *Allergy Eur J Allergy Clin Immunol* 52:58–64.
265 <https://doi.org/10.1111/j.1398-9995.1997.tb02546.x>

266

Declarations

Funding

This study was supported by the Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED under Grant Number JP21am0101123. This work was also supported by JSPS KAKENHI Grant Numbers JP20K11578, JP20H03392, and JP21K06560. Subsidy for Food Research funded by Kiriayama Scholarship Foundation

Competing interests

Authors Shuichi Otani, Soya Maeda, and Masayuki Suzuki are employed by Mitsui Norin Co. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Availability of data and material

The datasets during and/or analyzed during the current study available from the corresponding author on reasonable request.

Author Contributions

KI designed the study as the first author, and drafted the manuscript. YK, SO, and SM collected the test data. YA, NH, and MS helped in the interpretation of results. SN directed the research and reviewed the manuscript.

Figure Captions

Fig. 1 Schematic diagram representing a mouse model of OVA-induced FA

OVA sensitization, challenge, and TFs administration protocols in this study are shown.

FA, food allergy; i.p., intraperitoneal; OVA, ovalbumin; p.o., peroral. TFs, theaflavins.

Fig. 2 Effect of TFM on diarrhea symptoms in OVA-induced FA mice

Fecal condition was scored by severity when mice were fed normal diet (ND), 0.1% TFM, and 0.2% TFM. (A) Diarrhea symptoms during the study (up to the 12th OVA challenge). (B) Diarrhea symptoms of the 12th OVA challenge. Data are expressed as mean \pm standard error (n = 10). * $P < 0.05$ (Dunn's multiple comparisons test).

FA, food allergy; ND, normal diet; OVA, ovalbumin; TFM, theaflavin mixture.

Fig. 3 Effects of TFM, TFM-lc, and TF1 on diarrhea symptoms in OVA-induced FA mice

Fecal condition was scored by severity when mice were fed normal diet (ND), 0.20% TFM, 0.20% TFM-lc, and 0.02% TF1. (A) Diarrhea symptoms up to the 12th OVA challenge. (B) Diarrhea symptoms of the 12th OVA challenge. Data are expressed as mean \pm standard error (n = 9 or 10). * $P < 0.05$, ** $P < 0.01$ (Dunn's multiple comparisons test).

FA, food allergy; ND, normal diet; OVA, ovalbumin; TFM, theaflavin mixture; TFM-lc, TFM-low catechins; theaflavin 1, TF1.

Fig. 4 MDA levels in colon tissue of OVA-induced FA mice

MDA levels in colon tissue were measured when mice were fed normal diet (ND), 0.2% TFM, 0.2% TFM-lc, and 0.02% TF1. Colon tissue was obtained 3 days after the 12th OVA challenge, again from mice that had been orally administered OVA. Data are expressed as mean \pm standard error (n = 9 or 10). * $P < 0.05$ (Dunnett's multiple comparisons test).

FA, food allergy; MDA, malondialdehyde; ND, normal diet; OVA, ovalbumin; TFM, theaflavin mixture; TFM-lc, TFM-low catechins; theaflavin 1, TF1.

Supplemental Table 1. The content of TFs and catechins in TFM and TFM-lc as a percentage of dry matter

C, catechin; Cg, catechin gallate; EC, epicatechin; ECg, epicatechin gallate; EGC, epigallocatechin; EGCg, epigallocatechin gallate; GA, gallic acid; GC, gallocatechin; GCg, gallocatechin gallate; TFs, theaflavins; TFM, theaflavin mixture; TFM-lc, TFM-low catechins; TF1, theaflavin 1; TF2A, theaflavin 3-gallate; TF2B, theaflavin 3'-gallate; TF3, theaflavin 3, 3'-digallate.

Fig. 1




Fig. 2





Fig. 3






Fig. 4



Supplemental Table 1

Substance	Content (% of dry matter)	
	TFM	TFM-lc
TF1	7.03	8.62
TF2A	12.80	14.30
TF2B	5.80	6.58
TF3	16.39	19.17
GC	0.08	0.00
EGC	0.53	0.00
C	0.25	0.00
EGCg	4.24	0.00
EC	0.74	0.00
GCg	0.46	0.00
ECg	8.94	2.63
Cg	0.55	0.00
Caffeine	3.18	4.30
GA	0.04	0.00
Total theaflavins	42.02	48.67
Total catechins	15.79	2.63